vs
Journey Medical Corp（DERM）とSilvercrest Asset Management Group Inc.（SAMG）の財務データ比較。上の社名をクリックして会社を切り替えられます
Silvercrest Asset Management Group Inc.の直近四半期売上が大きい（$32.0M vs $16.1M、Journey Medical Corpの約2.0倍）。Silvercrest Asset Management Group Inc.の純利益率が高く（-0.4% vs -7.8%、差は7.4%）。Journey Medical Corpの前年同期比売上増加率が高い（27.3% vs -0.0%）。過去8四半期でJourney Medical Corpの売上複合成長率が高い（11.0% vs 2.7%）
Journey Medical Corpは商業段階のバイオ医薬品企業で、皮膚科領域の治療薬を専門としています。にきび、アトピー性皮膚炎、皮膚真菌感染症などに対応する処方薬や一般用医薬品を開発・製造・販売し、主に米国の医療従事者と患者にサービスを提供しています。
DERM vs SAMG — 直接比較
売上が大きい
SAMG
2.0倍大きい
$16.1M
売上成長率が高い
DERM
+27.3%の差
-0.0%
純利益率が高い
SAMG
純利益率が7.4%高い
-7.8%
2年売上CAGRが高い
DERM
2年複合成長率
2.7%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $16.1M | $32.0M |
| 純利益 | $-1.2M | $-120.0K |
| 粗利率 | — | — |
| 営業利益率 | -2.8% | -2.8% |
| 純利益率 | -7.8% | -0.4% |
| 売上前年比 | 27.3% | -0.0% |
| 純利益前年比 | -182.0% | -107.4% |
| EPS（希薄化後） | $-0.04 | $0.02 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上DERMSAMG
| Q4 25 | $16.1M | $32.0M | ||
| Q3 25 | $17.0M | $31.3M | ||
| Q2 25 | $15.0M | $30.7M | ||
| Q1 25 | $13.1M | $31.4M | ||
| Q4 24 | $12.6M | $32.0M | ||
| Q3 24 | $14.6M | $30.4M | ||
| Q2 24 | $14.9M | $31.0M | ||
| Q1 24 | $13.0M | $30.3M |
純利益DERMSAMG
| Q4 25 | $-1.2M | $-120.0K | ||
| Q3 25 | $-2.3M | $618.0K | ||
| Q2 25 | $-3.8M | $1.9M | ||
| Q1 25 | $-4.1M | $2.5M | ||
| Q4 24 | $1.5M | $1.6M | ||
| Q3 24 | $-2.4M | $2.3M | ||
| Q2 24 | $-3.4M | $2.7M | ||
| Q1 24 | $-10.4M | $3.0M |
粗利率DERMSAMG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
営業利益率DERMSAMG
| Q4 25 | -2.8% | -2.8% | ||
| Q3 25 | -9.0% | 4.3% | ||
| Q2 25 | -19.2% | 13.2% | ||
| Q1 25 | -25.3% | 15.4% | ||
| Q4 24 | 17.7% | 6.1% | ||
| Q3 24 | -19.8% | 14.6% | ||
| Q2 24 | -19.7% | 17.1% | ||
| Q1 24 | -77.4% | 19.5% |
純利益率DERMSAMG
| Q4 25 | -7.8% | -0.4% | ||
| Q3 25 | -13.6% | 2.0% | ||
| Q2 25 | -25.3% | 6.3% | ||
| Q1 25 | -31.0% | 7.9% | ||
| Q4 24 | 12.1% | 5.1% | ||
| Q3 24 | -16.3% | 7.4% | ||
| Q2 24 | -22.6% | 8.6% | ||
| Q1 24 | -80.1% | 9.9% |
EPS（希薄化後）DERMSAMG
| Q4 25 | $-0.04 | $0.02 | ||
| Q3 25 | $-0.09 | $0.07 | ||
| Q2 25 | $-0.16 | $0.21 | ||
| Q1 25 | $-0.18 | $0.26 | ||
| Q4 24 | $0.10 | $0.16 | ||
| Q3 24 | $-0.12 | $0.24 | ||
| Q2 24 | $-0.17 | $0.28 | ||
| Q1 24 | $-0.53 | $0.32 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $24.1M | $44.1M |
| 総負債低いほど良い | $25.3M | — |
| 株主資本純資産 | $31.9M | $50.3M |
| 総資産 | $94.6M | $166.6M |
| 負債/資本比率低いほどレバレッジが低い | 0.79× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資DERMSAMG
| Q4 25 | $24.1M | $44.1M | ||
| Q3 25 | $24.9M | $36.1M | ||
| Q2 25 | $20.3M | $30.0M | ||
| Q1 25 | $21.1M | $36.3M | ||
| Q4 24 | $20.3M | $68.6M | ||
| Q3 24 | $22.5M | $58.1M | ||
| Q2 24 | $23.9M | $49.9M | ||
| Q1 24 | $24.1M | $39.7M |
総負債DERMSAMG
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
株主資本DERMSAMG
| Q4 25 | $31.9M | $50.3M | ||
| Q3 25 | $25.9M | $58.9M | ||
| Q2 25 | $19.2M | $64.6M | ||
| Q1 25 | $21.5M | $80.0M | ||
| Q4 24 | $20.1M | $80.7M | ||
| Q3 24 | $10.9M | $84.6M | ||
| Q2 24 | $11.3M | $85.3M | ||
| Q1 24 | $13.0M | $83.9M |
総資産DERMSAMG
| Q4 25 | $94.6M | $166.6M | ||
| Q3 25 | $85.2M | $157.6M | ||
| Q2 25 | $81.2M | $152.7M | ||
| Q1 25 | $85.0M | $159.9M | ||
| Q4 24 | $80.2M | $194.4M | ||
| Q3 24 | $64.0M | $184.2M | ||
| Q2 24 | $65.2M | $177.6M | ||
| Q1 24 | $66.6M | $170.2M |
負債/資本比率DERMSAMG
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $-6.3M | $18.6M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $15.0M |
| FCFマージンFCF / 売上 | — | 46.9% |
| 設備投資強度設備投資 / 売上 | — | 11.4% |
| キャッシュ転換率営業CF / 純利益 | — | — |
| 直近12ヶ月FCF直近4四半期 | — | $17.0M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローDERMSAMG
| Q4 25 | $-6.3M | $18.6M | ||
| Q3 25 | $-2.4M | $14.6M | ||
| Q2 25 | $-942.0K | $13.8M | ||
| Q1 25 | $-2.8M | $-24.7M | ||
| Q4 24 | $2.2M | $21.6M | ||
| Q3 24 | $-1.2M | $13.3M | ||
| Q2 24 | $-5.2M | $16.0M | ||
| Q1 24 | $-5.0M | $-24.1M |
フリーキャッシュフローDERMSAMG
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $13.4M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $19.9M | ||
| Q3 24 | — | $12.9M | ||
| Q2 24 | — | $15.6M | ||
| Q1 24 | — | $-24.7M |
FCFマージンDERMSAMG
| Q4 25 | — | 46.9% | ||
| Q3 25 | — | 44.1% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | -80.0% | ||
| Q4 24 | — | 62.2% | ||
| Q3 24 | — | 42.4% | ||
| Q2 24 | — | 50.4% | ||
| Q1 24 | — | -81.6% |
設備投資強度DERMSAMG
| Q4 25 | — | 11.4% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 2.0% |
キャッシュ転換率DERMSAMG
| Q4 25 | — | — | ||
| Q3 25 | — | 23.62× | ||
| Q2 25 | — | 7.22× | ||
| Q1 25 | — | -10.01× | ||
| Q4 24 | 1.46× | 13.34× | ||
| Q3 24 | — | 5.90× | ||
| Q2 24 | — | 6.00× | ||
| Q1 24 | — | -8.03× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
